2011 Sessions Downloads

CoSMoS 2011 Presentations

August 1 – August 3, 2011
Chapel Hill, NC

Downloads (PDF Files unless otherwise noted)

Session 1
Improving Resolving Power and Sample Cleanliness for Complex Solutions
Session Chair: Ken Fountain, Waters Corporation

A Practical Approach in the Identification of Impurities for New Pharmaceutical Drug Candidates
— Angel Diaz, Pfizer

Differentiating Regioisomers of Hyroxylated Drug Metabolites with a High Resolution Qtof with Enhanced Ion Mobility Capabilities
— Joseph T. Marini, Covance Laboratories Inc.

LESA – Pesticides on Food
— Daniel Eikel, Advion BioSystems

Workshop 1
Future Directions of Novel Stationary Phases and High Resolution Instrumentation
— Session Chair: Ken Fountain, Waters Corporation

Session 2

Supercritical Fluid Chromatography
Session Chair: William Farrell, Pfizer

Expanding the Scope of Supercritical Fluid Chromatography
— Christine M. Aurigemma, Pfizer

Evaluation of SFC/MS/MS for Biomarkers in Pharmaceutical Research
— Elizabeth Groeber, Pfizer

Evolution of Analytical and Preparative SFC Units
— Manon Villeneuve, GlaxoSmithKline

Forced Degradation
Excipient Mediated Degradation

Session Chair: Karen Alsante, Pfizer
A Risk Management Approach to Color Selection for Pharmaceutical Dosage Forms (Presentation not available)
— Brian W. Pack, Eli Lilly & Company

Artifactual Formylation of the Secondary Amine of Duloxetine (Presentation not available)
— M.J. Skibic, Eli Lilly & Company

Characterization and Control of Reactive Components in Film Coatings
— Thomas P. Farrell, Colorcon

Workshop 2

Supercritical Fluid Chromatography (SFC) – “Science Fiction
Chromatography” or a Serious Contender

Workshop Chair: Wolfgang Goetzinger, Amgen

Forced Degradation Predictive Tools
Session Chair: Steve Baerschi, Eli Lilly & Company

Drug-Excipient Compatability: Investigation of the Mechanism of N-formylation of Amines by Reducing Sugars
— Patrick Jansen, Eli Lilly & Company

In Silico Prediction of Degradation Pathways: the Zeneth Program
— Martin A. Ott, Lhasa Limited

Session 3
Analysis of Botanicals/ Natural Products

Session Chair: Timothy R. Baker, Proctor & Gamble

Screening Complex Natural Product Mixtures for Antioxidants and Chemopreventative Agents
— Richard B. vanBreeman, University of Illinois College of Pharmacy

Quality Control of Medicinal Plants and Plant-derived Products by NMR Spectroscopy
— Hermann Stuppner, Institute of Pharmacy/Pharmacognosy, University of Innsbruck

UHPLC/UV/CAD/Q-tof-MS/MS Characterization of Botanical Mixtures
— Timothy R. Baker, Proctor & Gamble

Forced Degradation
Forced Degradation Case Studies and Degradation-Derived Genotoxic Impurities

Session Chair: Dan Reynolds, GlaxoSmithKline

Chemistry at the 2′ Position of Constituent Nucleotides Controls Degradation Pathways
— C. Jeffrey Calvitt, GlaxoSmithKline

Elucicating the Pathways of Degradation of Denagliptin
— Biren Joshi, GlaxoSmith Kline

Stress Testing and Degradation-Derived Genotoxic Impurities
— Steve Baertschi, Eli Lilly & Company

Workshop 3

Lab Start-up Considerations
Workshop Chair: Gary Bowers, GlaxoSmithKline

Forced Degradation
Predictive Tools

Session Chair: Steve Baertschi, Eli Lilly & Company

Critical Experimental Aspects of Oxidative Susceptibility Testing
— Paul Harmon, Merck & Company

Accelerated Stability Testing Protocol (ASAP) Theory & Practice
— Janice Ensing, Pfizer

Session 4
Trace Organic Analysis: Cutting Edge Applications

Session Chair: Daniel L. Norwood, PhD, Boehringer Ingelheim Pharmaceuticals, Inc.

Structural Analysis by NMR on the Microgram Scale: Expanding the Limits of Detection
— Dr. Nina C. Gonnella, Boehringer Ingelheim Pharmaceuticals, Inc.

Characterization of Trace Impurities Leaching from Pharmaceutical Packaging Systems
— Dr. Thomas N. Feinberg, Catalent Pharma Solutions

Identification, Quantitation, and Control of Trace Level Genotoxic Impurities in Organic Synthesis Intermediates and Final Products
— Dr. Kevin L. Facchine and Mr. Scott L. Sides, GlaxoSmithKline

Workshop 4
The Future of Trace Organic Analysis
Workshop Chair: Daniel L. Norwood, PhD, Boehringer Ingelheim Pharmaceuticals, Inc.

NMR in Trace Analysis: The Future of CE-NMR
— Roger Kautz, The Barnett Institute, Northeastern University

Structure Determination of Organic Microcrystals by Single Crystal X-ray Diffraction
— Christopher Ceccarelli, Agilent Technologies

What is CCC? Support-free Liquid Stationary Phase
— Guy Harris, Dynamic Extractions, Inc

Session 5
CSI Chapel Hill: Complex Sample Investigations

Session Chair: David Stranz, Sierra Analytics

Qualitative Characterization and Visualization of Complex Mixtures
— Doug Kiehl, Eli Lilly & Company

Phytoforensic Screening Technique for Rapid Detection of Novel Clandestine PDE-5 Inhibitor Analogues
— James Neal-Kababick, Flora Research Laboratories

GCxGC-TOF-MS Analyses of a Complex Fire Sample and Fire Fighter Smoke Exposures
— Brian McCarry, McMaster University

Workshop 5
Wisdom of the Crowd

Session Chair: William Farrell, Pfizer

Difficulties in the Synthesis and Packing of 1.1um Superficially Porous Particles for Liquid Chromatography
— Laura E. Blue, University of North Carolina

Session 6
Universal Detection

Session Chair: William Farrell, Pfizer;

A Practical Approach for Response Factor Correction Utilizing CAD/UV Detection in Gradient HPLC
— Yelizaveta Babayan & Brian W. Pack, Eli Lilly and Company

Quantitative-NMR as a Detection Method for High-Throughput Sample Analysis
— Steve Hollis, Amgen

Investigating Universal Detection Systems for the Analysis of Pharmaceutical Preparations
— Joe Hutchinson, UTAS